This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
Study Type
OBSERVATIONAL
Enrollment
24
ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
Zuckerberg Cancer Center
New Hyde Park, New York, United States
First follow-up imaging assessment
Compare first follow-up imaging assessment at 2 months with tumor response as assessed by ctDNA level change from baseline
Time frame: 2 months
ctDNA Assessment Comparison
Compare ctDNA assessment at 2 months with earlier ctDNA measurements
Time frame: 2 months
Compare Signatera ctDNA test
Compare Signatera ctDNA test with another vendor
Time frame: 6 months
ctDNA, CA19-9, & CEA Response
Compare response of ctDNA with response of CA19-9 and CEA
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.